Sage Journals: Discover world-class research

Open access

Research article

First published 2020-7

Anti-JCV antibody index does not change during ocrelizumab-treatment

Torge Rempe, Aaron Carlson, Augusto Miravalle [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open access

Research article

First published 2025

Comparative evaluation of STRATIFY JCV™ and IMMUNOWELL™ assays for anti-JCV antibody detection in natalizumab-treated RRMS patients

Clara Grazia Chisari, Giulio Spampinato, Pina Crimì [...]

Therapeutic Advances in Neurological Disorders

Retricted access

Research article

First published 2024-10

Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres

Gloria Dalla Costa, Letizia Leocani, Marco Pisa [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2016-7

PML risk stratification using anti-JCV antibody index and L-selectin

Nicholas Schwab, Tilman Schneider-Hohendorf, Béatrice Pignolet [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2015-10

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy

Anke Vennegoor, Johannis A van Rossum, Chris H Polman [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2025-6

Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?

Sandra Vukusic, Florian Hubben, Antoine Gavoille [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2014-9

An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy

Robert L Carruthers, Dalia L Rotstein, Brian C Healy [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2006-04

Human demyelinating disease and the polyomavirus JCV

K Khalili, M K White

Multiple Sclerosis Journal

Retricted access

Review article

First published 2018-4

Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters

Nicholas Schwab, Tilman Schneider-Hohendorf, Tammy Hoyt [...]

Multiple Sclerosis Journal

Free access

Research article

First published 2011-7

Extinction of Tumor Antigen Expression by SF2/ASF in JCV-Transformed Cells

Elena Uleri, Sarah Beltrami, Jennifer Gordon [...]

Genes & Cancer

Search results